Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified December 2013 by National Institute of Allergy and Infectious Diseases (NIAID)
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT01490671
First received: December 8, 2011
Last updated: December 2, 2013
Last verified: December 2013
  Purpose

Preliminary research has shown that a vaginal gel containing the antiretroviral (ARV) drug tenofovir may reduce the risk of HIV infection in women when used near the time of sexual intercourse. This study will evaluate the safety of 1% tenofovir gel in HIV-uninfected pregnant women and their newborns when the gel is used once a day for a period of 28 days at a designated time during pregnancy.


Condition Intervention Phase
HIV Infections
Drug: 1% tenofovir gel
Drug: Placebo gel
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Phase 2 Expanded Safety Study of Tenofovir Gel in Pregnancy

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • Maternal outcomes: Grade 2 or higher adverse events (AEs) in select categories [ Time Frame: Measured through participant's last study visit, which will occur 30 days after delivery ] [ Designated as safety issue: Yes ]
    Categories include: specific laboratory abnormalities, specific genital/pelvic signs/symptoms, and pregnancy complications

  • Neonatal outcomes (first 30 days of life): All serious adverse events (SAEs) [ Time Frame: Measured through the 30 day follow-up visit ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetics of tenofovir in mothers [ Time Frame: Measured at Day 14 visit ] [ Designated as safety issue: No ]
    Blood samples will be collected pre- and post-tenfovoir dose to measure tenofovir levels and to estimate the maximum concentration (Cmax)

  • Self-reported product use captured through questionnaires [ Time Frame: Measured through participant's last study visit, which will occur 30 days after delivery ] [ Designated as safety issue: No ]
  • Adherence to study gel as indicated by study drug levels in blood sample [ Time Frame: Measured through participant's last study visit, which will occur 30 days after delivery ] [ Designated as safety issue: No ]
  • Adherence to study gel obtained by count of returned unused applicators [ Time Frame: Measured through participant's last study visit, which will occur 30 days after delivery ] [ Designated as safety issue: No ]

Estimated Enrollment: 384
Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1a (tenofovir gel)
Group 1a will include women with a gestational age range of 36 0/7 to 37 6/7 weeks; they will receive 1% tenofovir gel
Drug: 1% tenofovir gel
One applicator of 1% tenofovir gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
Placebo Comparator: Group 1b (placebo gel)
Group 1b will include women with a gestational age range of 36 0/7 to 37 6/7 weeks; they will receive placebo gel.
Drug: Placebo gel
One applicator of placebo gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
Experimental: Group 2a (tenofovir gel)
Group 2a will include women with a gestational age range of 28 0/7 to 32 6/7 weeks; they will receive 1% tenofovir gel.
Drug: 1% tenofovir gel
One applicator of 1% tenofovir gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
Placebo Comparator: Group 2b (placebo gel)
Group 2b will include women with a gestational age range of 28 0/7 to 32 6/7 weeks; they will receive placebo gel.
Drug: Placebo gel
One applicator of placebo gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
Experimental: Group 3a (tenofovir gel)
Group 3a will include women with a gestational age range of 20 0/7 to 24 6/7 weeks; they will receive 1% tenofovir gel.
Drug: 1% tenofovir gel
One applicator of 1% tenofovir gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
Placebo Comparator: Group 3b (placebo gel)
Group 3b will include women with a gestational age range of 20 0/7 to 24 6/7 weeks; they will receive placebo gel.
Drug: Placebo gel
One applicator of placebo gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
Experimental: Group 4a (tenofovir gel)
Group 4a will include women with a gestational age range of 12 0/7 to 16 6/7 weeks; they will receive 1% tenofovir gel.
Drug: 1% tenofovir gel
One applicator of 1% tenofovir gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
Placebo Comparator: Group 4b (placebo gel)
Group 4b will include women with a gestational age range of 12 0/7 to 16 6/7 weeks; they will receive placebo gel.
Drug: Placebo gel
One applicator of placebo gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first

Detailed Description:

Pregnant women often maintain sexual activity, and research has shown that they may have a greater risk of acquiring HIV infection during pregnancy. Preliminary research has suggested that tenofovir 1% gel, a vaginal microbicide, may reduce the risk of HIV infection for women when it is applied at the time of sexual intercourse. However, safety data on the use of tenofovir 1% gel during pregnancy are limited. This study will enroll pregnant women who will use tenofovir 1% gel on a daily basis for 28 consecutive days during their pregnancy, which is a longer period of use than has been studied previously. The purpose of this study is to evaluate the safety of 1% tenofovir gel in HIV-uninfected pregnant women when used during the late first trimester and second trimester of pregnancy.

Participants will be healthy, HIV-uninfected pregnant women and will be randomly assigned to use either 1% tenofovir gel or placebo gel once a day for 28 days or until delivery, whichever comes first. Participants will be further divided into four groups of varying gestational age ranges. These groups will be filled sequentially, starting with the later gestational ages (closer to the time of delivery) group first. Once the safety for this group is confirmed, groups of participants with earlier gestational ages will be enrolled.

Length of participation in this study will vary depending on gestational age at the time of enrollment, but each participant will have visits at study entry; Days 7, 14, and 28; 2 weeks after the last dose of the assigned gel; and once every 4 weeks until delivery. Participants who have used the gel within 24 hours of arriving at the hospital for delivery also will have a delivery visit. At most visits, participants will give a medical history; undergo blood and urine collection; and have a physical exam, including obstetric (OB) abdominal and pelvic exams. Participants also will report adverse events and complete an adherence assessment. If a participant has a delivery visit, blood will be collected from the umbilical cord and delivery and infant information will be collected. All participants will attend a follow-up study visit 30 days after delivery.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 18 through 45 years (inclusive) at screening, verified per site standard operating procedures (SOPs)
  • At enrollment, singleton, viable pregnancy of gestational age within the limits for current group for enrollment
  • Per participant report, sexually active, defined as having vaginal intercourse at least once in the 3 months prior to screening
  • Able and willing to provide the following:

    • Written informed consent to be screened for and take part in the study
    • Adequate locator information, as defined in site SOPs
    • Adequate documentation of entry to antenatal care, as defined in site SOPs
    • Permission to contact and provision of adequate contact information for participant's antenatal care provider
    • Permission to obtain copies of antenatal care records More information on this criterion can be found in the protocol.
  • HIV-uninfected based on testing performed by study staff at screening and enrollment (per algorithm in protocol)
  • Per the clinical judgment of the Investigator of Record (IoR)/designee at enrollment, pelvic exam (including cervical exam) normal for estimated gestational age and parity
  • Per the clinical judgment of the IoR/designee at enrollment, ultrasound results are complete, consistent with normal singleton intrauterine pregnancy, and provide an assessment of gestational age. More information on this criterion can be found in the protocol.
  • Per participant mother report, willingness by the participant mother to receive information regarding and consider participation in MTN-016, a pregnancy registry study that collects additional information on pregnancy safety and the growth and development of babies up to 1 year of age
  • At screening and enrollment, agrees not to participate in other research studies involving drugs, vaccines, medical devices, or vaginal products for the duration of study participation

Exclusion Criteria:

  • Participant mother reported any of the following:

    • Prior exposure to gel or oral formulation of tenofovir (ever)
    • Known sensitivity to any component of the study products (ever)
    • Post-exposure prophylaxis (PEP) for HIV exposure within 6 months prior to enrollment
    • Participation in any research study involving drugs, medical devices, or vaginal products during the current pregnancy
    • Non-therapeutic injection drug use in the 12 months prior to screening
  • By participant mother report, noted on antenatal record, or clinical evidence at the time of enrollment of any of the following in the current pregnancy:

    • Multiple gestation
    • Placenta previa
    • Cervical cerclage
    • Abnormal fetal anatomy (in the opinion of the IoR or designee)
    • Intrauterine growth restriction
    • Pre-existing or gestational diabetes
    • Hypertensive disorder of pregnancy
    • Treatment for preterm labor
  • By participant mother report, or noted on review of medical record, any of the following in a previous pregnancy:

    • Intrauterine growth restriction
    • Gestational diabetes
    • Hypertensive disorder of pregnancy
    • Intrauterine fetal demise (estimated gestational age 20 weeks or greater)
    • Delivery prior to 37 0/7 weeks
  • By participant mother report at screening or enrollment:

    • Intends to relocate away from the study site during the period of expected study visits
    • Plans to travel away from the study site during the expected study product dosing period, such that travel would preclude the completion of one or more scheduled study visits
    • Plans to deliver outside of a hospital. More information on this criterion can be found in the protocol.
  • Currently breastfeeding
  • As determined by the IoR/designee, any significant uncontrolled active or chronic cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, respiratory, immunologic disorder or infectious disease, including active tuberculosis, or medication use that would make study participation unsafe. More information on this criterion can be found in the protocol.
  • At enrollment, clinically apparent Grade 2 or higher pelvic exam finding (observed by study staff). More information on this criterion can be found in the protocol.
  • Has any of the following laboratory abnormalities during the screening period:

    • Hemoglobin value of Grade 3 or higher according to Division of AIDS (DAIDS) Toxicity Table
    • Platelet count less than 100,000 mm^3
    • Aspartate aminotransferase (AST) or alanine transaminase (ALT) greater than 1.5 times the upper limit of normal
    • Serum creatinine greater than 1.0 mg/dL
    • Hepatitis B surface antigen (HBsAg) positivity
    • Urine dipstick positive for protein greater than or equal to 2
    • Urine dipstick positive for glucose greater than or equal to 2
    • Positive for malaria (at sites with capacity, where women are at risk and testing through antenatal care provider is not otherwise available)
    • More information on this criterion can be found in the protocol
  • Grade 2 or higher Pap result (e.g., high-grade squamous intraepithelial lesion). More information on this criterion can be found in the protocol.
  • Diagnosed with a sexually transmitted infection or reproductive tract infection requiring treatment, per current Centers for Disease Control and Prevention (CDC) or World Health Organization (WHO) guidelines, as applicable. More information on this criterion can be found in the protocol.
  • Has any other condition that, in the opinion of the IoR/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01490671

Sponsors and Collaborators
Investigators
Study Chair: Richard H Beigi, MD, MSc Magee-Womens Hospital
Study Chair: Bonus Makanani, MBBS, FCOG (SA) University of Malawi College of Medicine
  More Information

Publications:
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT01490671     History of Changes
Other Study ID Numbers: MTN-019, 11839
Study First Received: December 8, 2011
Last Updated: December 2, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Tenofovir
Tenofovir disoproxil
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Anti-HIV Agents

ClinicalTrials.gov processed this record on October 16, 2014